Also found in: Medical.
NK1Neurokinin Receptor 1
References in periodicals archive ?
Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK1 RA to significantly reduce CINV in both the acute phase (0 - 24 hours after chemotherapy) and the delayed phase (24 - 120 hours after chemotherapy).
In samples collected after 45 days of incubation, diabetic mice presented a reduced influx of TCD4+ cells (CD3+/CD4+; Figure 4(a)), TCD8+ cells (CD3+/CD8+; Figure 4(b)), B lymphocytes (CD19+; Figure 4(c)), NK cells (NK1.1+/CD3-; Figure 4(d)), and dendritic cells (CD11c+/CD80+; Figure 4(f)) when compared to control infected groups.
Maggi, "Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors," British Journal of Cancer, vol.
Fertilizer doses with N and K were as follows: NK0 = no fertilizer was applied; NK1 = an application of 50% of the standard recommendation of N and K (175 kg [ha.sup.-1] of N and 285 kg [K.sub.2]O [ha.sup.-1] [year.sup.-1]); NK2 = an application of 100% of the standard recommendation of N and K (350 kg [ha.sup.-1] of N and 570 kg [K.sub.2]O [ha.sup.-1] [year.sup.-1]); and NK3 = an application of 150% of standard recommendation of N and K (525 kg N [ha.sup.-1] and 855 kg [K.sub.2]O [ha.sup.-1] [year.sup.-1]).
O maropitant e um anti-emetico de acao central que atua bloqueando os receptores da neurocinina-1 (NK1) no SNC.
Spinal NK1 receptors contribute to the increased excitability of the nociceptive flexor reflex during persistent peripheral inflammation.
Now working their way through the developmental pipeline are two promising novel classes of drugs designed to target the physiologic mechanisms underlying this common and challenging problem: neurokinin 1 (NK1) receptor antagonists and selective opioid receptor agonists, explained Dr.
Aprepitant belongs to a class of agents known as NK1 receptor antagonists, which are often used in combination with 5-HT3 receptor antagonists for the prevention of CINV.
Upon removal of red bodies and centrifugation, immune cells were incubated with fluorochrome-conjugated antibodies and characterized according to two different panels, a myeloid panel: CD45-BV510 (103138, BioLegend), 7AAD-PE-Cy5-YG (420404, BioLegend), CD11b-BV711 (101242, BioLegend), F4/80APC (17-4801-82, eBiosciences), MHC2-Alexa700 (107622, BioLegend), CD11c-PE-Cy7 (25-0114-81, eBiosciences), and Ly6G-FITC (551460, BD Pharmingen) and a lymphoid panel: CD45-BV510 (103138, BioLegend), 7AAD-PE-Cy5-YG (420404, BioLegend), CD3-PE-Cy7 (25-0031-82, eBiosciences), CD4-FITC (11-0041-85, eBiosciences), CD8-PerCpCy5.5 (126610, BioLegend), and NK1.1-BV711 (108745, BioLegend).
Wang, "Increased expression of SP and NK1 receptor in rat colon of chronic visceral hypersensitivity," Chinese Journal of Gastroenterology & Hepatology, vol.
Aprepitant is a neurokinin-1 (NK1) receptor antagonist and is the first of its class to be approved for use [3].